$2.79 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 103 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | HORIZON PHARMA PLC | $129,422,000 | +18.2% | 6,609,894 | 0.0% | 4.64% | +20.6% | |
| FIXX | HOMOLOGY MEDICINES INC | $119,490,000 | +12.1% | 5,227,035 | 0.0% | 4.28% | +14.3% | |
| HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $99,537,000 | +4.9% | 99,100,000 | 0.0% | 3.57% | +7.0% | ||
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $65,134,000 | +16.4% | 2,900,000 | 0.0% | 2.33% | +18.8% | |
| KEMPHARM INCnote 5.500% 2/0 | $48,281,000 | -12.9% | 75,000,000 | 0.0% | 1.73% | -11.2% | ||
| SRPT | SAREPTA THERAPEUTICS INC | $47,807,000 | +22.2% | 296,000 | 0.0% | 1.71% | +24.6% | |
| WRIGHT MED GROUP N Vnote 2.250%11/1 | $45,572,000 | +8.7% | 31,500,000 | 0.0% | 1.63% | +10.8% | ||
| CVS | CVS HEALTH CORPcall | $44,618,000 | +22.3% | 566,800 | 0.0% | 1.60% | +24.7% | |
| XERS | XERIS PHARMACEUTICALS INC | $43,927,000 | -7.4% | 2,498,666 | 0.0% | 1.57% | -5.5% | |
| EDIT | EDITAS MEDICINE INC | $36,874,000 | -11.2% | 1,158,841 | 0.0% | 1.32% | -9.4% | |
| INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $36,248,000 | +14.7% | 36,000,000 | 0.0% | 1.30% | +16.9% | ||
| UHS | UNIVERSAL HLTH SVCS INCcl b | $33,494,000 | +14.7% | 262,000 | 0.0% | 1.20% | +17.1% | |
| K2M GROUP HLDGS INCnote 4.125% 8/1 | $30,080,000 | +15.5% | 20,000,000 | 0.0% | 1.08% | +17.8% | ||
| DFBHU | DFB HEALTHCARE ACQUISTION COunit 01/30/2023 | $25,500,000 | +0.5% | 2,500,000 | 0.0% | 0.91% | +2.5% | |
| SYBX | SYNLOGIC INC | $19,399,000 | +44.6% | 1,365,143 | 0.0% | 0.70% | +47.6% | |
| MOR | MORPHOSYS AGsponsored ads | $16,020,000 | -12.0% | 600,000 | 0.0% | 0.57% | -10.2% | |
| ZBH | ZIMMER BIOMET HLDGS INC | $15,908,000 | +18.0% | 121,000 | 0.0% | 0.57% | +20.3% | |
| ARDX | ARDELYX INC | $15,190,000 | +17.6% | 3,491,922 | 0.0% | 0.54% | +19.8% | |
| SYRS | SYROS PHARMACEUTICALS INC | $15,113,000 | +16.6% | 1,268,945 | 0.0% | 0.54% | +18.9% | |
| GTHX | G1 THERAPEUTICS INC | $15,007,000 | +20.3% | 287,000 | 0.0% | 0.54% | +22.8% | |
| CBAY | CYMABAY THERAPEUTICS INC | $14,882,000 | -17.4% | 1,343,181 | 0.0% | 0.53% | -15.8% | |
| AACH | AAC HLDGS INC | $14,146,000 | -18.6% | 1,853,998 | 0.0% | 0.51% | -16.9% | |
| CTMX | CYTOMX THERAPEUTICS INC | $13,504,000 | -19.1% | 729,948 | 0.0% | 0.48% | -17.4% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $11,951,000 | -28.4% | 2,722,241 | 0.0% | 0.43% | -27.0% | |
| TELIGENT INC NEWnote 4.750% 5/0 | $10,401,000 | +0.9% | 9,567,000 | 0.0% | 0.37% | +3.0% | ||
| NUVASIVE INCnote 2.250% 3/1 | $8,865,000 | +16.8% | 7,000,000 | 0.0% | 0.32% | +19.1% | ||
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $7,668,000 | +14.5% | 250,000 | 0.0% | 0.28% | +17.0% | |
| RARX | RA PHARMACEUTICALS INC | $6,923,000 | +81.8% | 382,700 | 0.0% | 0.25% | +85.1% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $6,894,000 | +25.4% | 280,000 | 0.0% | 0.25% | +28.0% | |
| ALIM | ALIMERA SCIENCES INC | $5,932,000 | +0.2% | 6,052,935 | 0.0% | 0.21% | +1.9% | |
| ALBO | ALBIREO PHARMA INC | $3,955,000 | -7.2% | 120,000 | 0.0% | 0.14% | -5.3% | |
| IGI LABORATORIES INCnote 3.750%12/1 | $3,555,000 | +2.3% | 3,733,000 | 0.0% | 0.13% | +4.1% | ||
| TLGT | TELIGENT INC NEW | $2,800,000 | +14.1% | 708,873 | 0.0% | 0.10% | +16.3% | |
| PRTO | PROTEON THERAPEUTICS INC | $2,389,000 | -20.4% | 1,224,899 | 0.0% | 0.09% | -18.1% | |
| VYGR | VOYAGER THERAPEUTICS INC | $2,226,000 | -3.2% | 117,647 | 0.0% | 0.08% | -1.2% | |
| EYEN | EYENOVIA INC | $1,206,000 | -36.2% | 300,000 | 0.0% | 0.04% | -34.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.